(Reuters) - WASHINGTON, April 9 - Johnson & Johnson's bladder drug Ditropan needs stronger cautions about the risk of hallucination and similar problems in children and older patients, U.S. Food and Drug Administration staff said in documents released on Monday.
The drug, also known as oxybutynin, already lists insomnia, nervousness, confusion and other central nervous system risks on its label, but staff reviewers said more explicit cautions are needed.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment